866Bacillus calmette-guerin versus chemotherapy in thi intravesical treatment of carcinoma in situ: A meta analysis of the published results of randomized clinical trials

2005 ◽  
Vol 4 (3) ◽  
pp. 219
Author(s):  
R. Sylvester ◽  
A. Van der Meijden ◽  
J.A. Witjes ◽  
K. Kurth
Keyword(s):  
Clinical Trials ◽  
Carcinoma In Situ ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Intravesical Treatment

scholarly journals Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?

2019 ◽  
Vol 26 (2) ◽  
pp. 665-671 ◽  
Author(s):  
Gábor Cserni ◽  
Anita Sejben
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Ductal Carcinoma In Situ ◽  
Invasive Breast Cancer ◽  
Lower Risk ◽  
Carcinoma In Situ ◽  
Randomized Clinical Trials ◽  
Ductal Carcinoma ◽  
High Grade

AbstractDuctal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

Sign in / Sign up

Export Citation Format

Share Document